

Myriad Genetics is a molecular diagnostic company at the forefront of one of the most exciting areas in healthcare – **predictive medicine, prognostic medicine** and **personalized medicine**. With a deep understanding of the roles genes play in human disease, the Company has developed and commercializes products that assess a person's risk of developing disease later in life and help guide treatment decisions. These products have the potential of improving the healthcare and quality of life of patients, reducing healthcare costs and, most importantly, saving lives.

The Company offers the most accurate clinical tests available to determine predisposition to hereditary breast cancer, ovarian cancer, colon cancer, endometrial cancer and melanoma skin cancer. The Company is also a leader in the personalized medicine field, offering clinical tests that guide therapeutic decisions for patients with breast cancer, colon cancer and prostate cancer.

Multiple Opportunities for Continued Growth

Global leader and pioneer in molecular diagnostics field

- Eight innovative, high value products representing a \$2.7 billion total annual market opportunity
- A sales force 300-strong


Uniquely positioned to develop and commercialize new diagnostic products

- Goal is to introduce at least one new test per year; Targeting two new products in calendar 2010

Sustainable competitive advantage

- Strong patent portfolio
- Significant market share
- Differentiated products
- Enhanced professional society guidelines for testing (SGO/ACOG)
- Robust insurance reimbursement/lower overall healthcare costs

Marketed Product	Application
BRACAnalysis [®]	Hereditary breast and ovarian cancer
COLARIS [®]	Hereditary uterine and colorectal cancer
COLARIS AP [®]	Other major colon cancer syndrome
MELARIS [®]	Hereditary melanoma
OnDose [®]	5-FU chemotherapy dosing
PREZEON [™]	PTEN gene status
TheraGuide [®] 5-FU	5-FU chemotherapy toxicity
prolaris	Prostate cancer




NASDAQ Global Select Market: **MYGN**

FY 2010 Highlights

- Record net profit of \$152.3 million, or \$1.54 per diluted share, versus net profit of \$84.6 million, or \$0.86 per share, in year ending June 30, 2010, and June 30, 2009, respectively
- Molecular diagnostic revenues rose 11% to \$363 million from \$327 million in year ending June 30, 2010, and June 30, 2009, respectively
 - Enhanced sales and marketing efforts;
 - Direct-to-consumer advertising campaign;
 - Increased physician acceptance
- Improved margins resulting from greater operating efficiencies in Company's molecular diagnostics laboratory
 - 88% gross profit margin

Strong Annual Revenue Growth



Recent Price (8/6/10): \$15.39

52-Week Range (8/6/10): \$14.11–\$31.95

Shares Outstanding: 94 million

Cash and Investments: \$488 million

Debt: None

Founded: 1991

Year-End: June 30

Contact:

Suzanne Barton
 Investor Relations
 801-584-3600
 Myriad Genetics, Inc.
 320 Wakara Way
 Salt Lake City, UT 84108